Correction to: Effects of Galcanezumab on Health-Related Quality of Life and Disability in Patients with Previous Failure of 2-4 Migraine Preventive Medication Categories: Results from a Phase IIIb Randomized, Placebo-Controlled, Multicenter Clinical Trial (CONQUER)
Clin Drug Investig. 2022 Mar;42(3):277.
doi: 10.1007/s40261-022-01123-z.
1 Department of Neurology, Geisel School of Medicine at Dartmouth, 1 Rope Ferry Rd, Hanover, NH, 03755, USA.
2 Department of Neurology, Medstar Georgetown University, 3800 Reservoir Rd NW, Washington, DC, 20007, USA.
3 Health Outcomes and Real-World Evidence, Biomedicines, Eli Lilly and Company, Lilly Corporate Center, 893 Delaware St, Indianapolis, IN, 46285, USA. [email protected].
4 Clinical, Eli Lilly and Company, Lilly Corporate Center, 893 Delaware St, Indianapolis, IN, 46285, USA.
5 Department of Statistics-Neuroscience/Urology, Eli Lilly and Company, Lilly Corporate Center, 893 Delaware St, Indianapolis, IN, 46285, USA.
6 Departments of Statistics, IQVIA, 4820 Emperor Blvd, Durham, NC, 27703, USA.
7 GPORWE International, Eli Lilly and Company, Bracknell, RG12 1PU, UK.